{"denoms":[{"counts":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"42"}],"units":"Participants"}],"groups":[{"description":"Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.","id":"BG000","title":"Rasburicase Group"},{"description":"Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.","id":"BG001","title":"Control Group"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"20","upperLimit":"59","value":"42.9"},{"groupId":"BG001","lowerLimit":"21","upperLimit":"55","value":"45"},{"groupId":"BG002","lowerLimit":"20","upperLimit":"59","value":"44"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"23"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]}],"title":"MRD: Cyclsporine + Methotrexate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"MRD: Tacrolimus + Methotrexate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"}]}],"title":"MUD: Tacrolimus + Methotrexate + ATG"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"title":"MUD: Tacrolimus + Methotrexate"}],"description":"Participants received GVHD prophylaxis at the investigator's discretion. MRD=matched related donor. MUD=matched unrelated donor. ATG=antithymocyte globulin.","paramType":"COUNT_OF_PARTICIPANTS","title":"Graft-Versus-Host Disease (GVHD) Prophylaxis Intervention","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"28"}]}],"title":"Busulfan + Cyclophosphamide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}],"title":"Busulfan + Fludarabine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]}],"title":"Total Body Irradiation + Cyclophosphamide"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Conditioning Protocol Interventions","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat participants included in the analyses."}